Is the price fair?
What INSM's price assumes
Insmed Incorporated did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 43.0× revenue.
43.0
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 50.0
Price / book · as of 2026-Q1
- EV / sales
- 43.0
EV / sales
Details›
- Price / book2026-Q1
- 50.0
- EV / EBIToperating margin −74%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 43.0
- Market capitalisation
- $20.8B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
Ranks #140 of 145 by Smart Score